IRIS
CASTIGLIONE, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.233
AS - Asia 6.403
EU - Europa 4.828
SA - Sud America 1.568
AF - Africa 189
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 2
Totale 24.240
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.754
SG - Singapore 2.468
CN - Cina 1.697
RU - Federazione Russa 1.687
BR - Brasile 1.250
IT - Italia 1.132
VN - Vietnam 897
HK - Hong Kong 474
GB - Regno Unito 418
DE - Germania 322
CA - Canada 296
FR - Francia 256
FI - Finlandia 236
IN - India 154
IE - Irlanda 143
MX - Messico 128
TR - Turchia 124
BD - Bangladesh 109
NL - Olanda 107
AR - Argentina 106
PL - Polonia 90
UA - Ucraina 87
SE - Svezia 83
ID - Indonesia 74
ZA - Sudafrica 69
IQ - Iraq 66
ES - Italia 65
PK - Pakistan 58
EC - Ecuador 55
AT - Austria 47
JP - Giappone 46
IL - Israele 44
CO - Colombia 38
VE - Venezuela 31
AE - Emirati Arabi Uniti 27
MA - Marocco 27
UZ - Uzbekistan 27
PY - Paraguay 26
LT - Lituania 25
CL - Cile 21
PE - Perù 18
SA - Arabia Saudita 18
EG - Egitto 17
RO - Romania 16
KE - Kenya 14
TN - Tunisia 14
AU - Australia 13
CH - Svizzera 13
DZ - Algeria 13
PH - Filippine 13
AL - Albania 11
BE - Belgio 11
DO - Repubblica Dominicana 11
AZ - Azerbaigian 10
CR - Costa Rica 10
UY - Uruguay 10
CZ - Repubblica Ceca 9
DK - Danimarca 9
JO - Giordania 9
MY - Malesia 9
BO - Bolivia 8
GR - Grecia 8
MC - Monaco 8
SN - Senegal 8
TW - Taiwan 7
CI - Costa d'Avorio 6
HU - Ungheria 6
IR - Iran 6
JM - Giamaica 6
KZ - Kazakistan 6
NP - Nepal 6
OM - Oman 6
PA - Panama 6
GT - Guatemala 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
AM - Armenia 4
BG - Bulgaria 4
BH - Bahrain 4
BY - Bielorussia 4
GY - Guiana 4
HN - Honduras 4
LV - Lettonia 4
MD - Moldavia 4
PS - Palestinian Territory 4
SI - Slovenia 4
AO - Angola 3
KR - Corea 3
LB - Libano 3
NI - Nicaragua 3
NO - Norvegia 3
PT - Portogallo 3
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BT - Bhutan 2
CG - Congo 2
ET - Etiopia 2
GD - Grenada 2
GE - Georgia 2
HR - Croazia 2
Totale 24.188
Salva come PNG Salva come JPEG
Città #
Dallas 2.450
Singapore 1.392
Chicago 862
Ashburn 785
San Jose 716
Beijing 615
Los Angeles 607
Hong Kong 459
Salt Lake City 393
Moscow 317
Ho Chi Minh City 302
Buffalo 251
Tampa 204
Hanoi 200
Chandler 181
Elk Grove Village 167
New York 167
Helsinki 152
São Paulo 148
Dublin 141
Council Bluffs 129
Lauterbourg 127
The Dalles 124
Boardman 121
Santa Clara 115
Wilmington 111
Hefei 108
Milan 107
Munich 102
Rome 94
Pisa 91
Beauharnois 89
Fairfield 84
Orem 83
San Mateo 82
Sterling 81
Warsaw 78
Lancaster 72
London 72
Montreal 72
Florence 67
Cambridge 65
Houston 65
Seattle 64
Frankfurt am Main 63
Istanbul 63
Mexico City 62
Denver 61
Poplar 60
Amsterdam 59
Miami 58
Toronto 55
Atlanta 54
Stockholm 54
Phoenix 52
Brooklyn 49
Dulles 48
Chennai 45
Da Nang 45
Johannesburg 45
Lappeenranta 44
Tokyo 44
Ottawa 43
Rio de Janeiro 41
Nuremberg 40
Portsmouth 40
Stevenage 38
Turku 35
Tel Aviv 34
Detroit 33
Southend 33
Boston 32
Falls Church 32
Manchester 32
Belo Horizonte 31
Kansas City 31
Lawrence 30
Washington 30
Woodbridge 30
Haiphong 29
Ankara 28
Jacksonville 28
Guangzhou 27
Lucca 27
Bologna 26
Hangzhou 26
Paris 26
Porto Alegre 25
Palermo 24
Pittsburgh 24
Tashkent 24
Guayaquil 22
Mumbai 22
Curitiba 21
San Francisco 21
Shanghai 21
Shenzhen 21
Genoa 20
New Delhi 20
Quito 20
Totale 14.760
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.830
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.673
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 698
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 597
A simple echocardiographic score to rule out cardiac amyloidosis 358
A simple echocardiographic score to rule out cardiac amyloidosis 324
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 311
[Central apneas and cardiovascular diseases] 302
Using co-creation to develop a cardiology online open course: an effective approach for implementing digital learning 293
[Treatment of cardiac fibrosis: from neurohormonal antagonists to CAR-T cells] 279
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 255
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 252
Atrial amyloidosis: mechanisms and clinical manifestations 248
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 247
Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies 242
Biomarkers for the diagnosis and management of heart failure: New frontiers 242
The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy 241
Unveiling a sudden unexplained death case by whole exome sequencing and bioinformatic analysis 241
Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease 240
Eligibility for vericiguat in a real‐world, contemporary heart failure population 239
RNA-targeting and gene editing therapies for transthyretin amyloidosis 238
Biomarkers for the diagnosis and management of heart failure 237
Prognostic value of right ventricular refractory period heterogeneity in Type-1 Brugada electrocardiographic pattern 236
Role of Imaging in Cardiomyopathies 228
Myocardial salvage is increased after sympathetic renal denervation in a pig model of acute infarction 228
Cardiac magnetic resonance in patients with muscular dystrophies 224
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 224
Approccio critico all’interpretazione dei trial cardiovascolari con risultati neutri o negativi 223
Myocardial Infarction Following COVID-19 Vaccine Administration: Post Hoc, Ergo Propter Hoc? 221
Cardiovascular disease and COVID-19: les liaisons dangereuses 220
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 219
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 219
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan 218
Disease features and management of cardiomyopathies in women 218
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 215
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 209
Valvular heart disease in patients with cardiac amyloidosis 205
Scared to Death: Emotional Stress Causing Fatal Myocardial Infarction With Nonobstructed Coronary Arteries in Women 205
Cardiac amyloidosis: Innovations in diagnosis and treatment 204
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 204
Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets 203
Tissue Characterization in Cardiac Amyloidosis 202
Molecular autopsy of sudden cardiac death in the genomics era 200
Valve disease in cardiac amyloidosis: an echocardiographic score 195
Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias 195
Cardiac Amyloidosis: How Its Epidemiology is Changing 194
Cardiovascular toxicity from therapies for light chain amyloidosis 193
Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis 188
Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction 188
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 188
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 186
Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy 182
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week 181
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis 181
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 180
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 179
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 178
Sex differences in transthyretin cardiac amyloidosis 178
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) 178
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 177
PET and Cardiac Amyloidosis 177
Right heart failure in left heart disease: imaging, functional, and biochemical aspects of right ventricular dysfunction 176
Current and emerging drug targets in heart failure treatment 175
Prevalence and functional impact of chronotropic incompetence in amyloid cardiomyopathy: a multicentre analysis 173
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 173
Pathophysiology of Cardiac Amyloidosis 172
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy 172
Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study 172
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction 171
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction 167
Coronary Artery Anomalies 166
Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond 161
Obstructive sleep apnea and cardiovascular diseases 160
Positron emission tomography in cardiac amyloidosis: current evidence and future directions 157
The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 156
Use of biomarkers to diagnose and manage cardiac amyloidosis 155
What Is Hidden Behind Inferior Negative T Waves: Multiple Cardiac Glomangiomas 155
Chest pain after elective percutaneous coronary intervention as trigger of takotsubo syndrome-a case report 154
Gamma-glutamyltransferase independently predicts mortality and hospitalization for heart failure in cardiac transthyretin amyloidosis 151
Treatment of cardiac transthyretin amyloidosis: an update 151
Critical Reading of cardiovascular trials with neutral or negative results 149
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 148
Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis 148
Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure? 145
Safety and Efficacy of Amiodarone in a Patient With COVID-19 144
Cardiac Biomarkers in Patients With Suspected Amyloid (Transthyretin) Cardiomyopathy: Which Cut-Offs? 143
Stroke in ATTR cardiac amyloidosis: Does only rhythm matter? 141
Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines 141
Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease 138
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 136
Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis 132
Is targeting cyclic guanosine monophosphate by vericiguat effective to treat ischaemic heart failure with reduced ejection fraction? Yes, it is 130
The Left Ventricular Mass-to-Strain Ratio: Enough to Differentiate ATTR From AL Cardiac Amyloidosis? 127
Cost-effectiveness of transthyretin cardiac amyloidosis screening and treatment: A Dilemma for the clinician 126
Statin therapy in COVID-19 infection 123
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 122
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism 122
The unbearable underreporting of comorbidities in heart failure clinical trials 121
Characterization of Phenotypic Variability in Becker Muscular Dystrophy for Clinical Practice and Towards Trial Readiness: A Two-Years Follow up Study 119
Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift 117
Totale 23.219
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.099
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.099
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021122 0 0 0 0 0 0 0 0 0 24 49 49
2021/2022544 45 67 17 39 25 62 45 94 58 50 7 35
2022/2023563 33 61 23 50 58 71 23 49 103 22 51 19
2023/2024756 43 15 140 74 47 65 53 31 27 47 31 183
2024/20258.178 51 97 231 132 304 256 611 1.146 434 1.070 2.215 1.631
2025/202613.877 851 2.039 2.152 2.068 1.505 1.042 1.411 772 1.128 909 0 0
Totale 24.374